Dyne Therapeutics, Inc. DYN
Institutional shares held
103 Million
135K
calls
435K
puts
Total value of holdings
$1.18B
$1.55M
calls
$4.98M
puts
Market Cap
$593M
51,765,400
Shares Out.
Institutional ownership
198.35%
# of Institutions
212
We take great care to ensure that the data presented and summarized in this overview for Dyne Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding DYN
View all-
Atlas Venture Life Science Advisors, LLC8.02MShares$91.8 Million31.16% of portfolio
-
Black Rock Inc. New York, NY7.39MShares$84.6 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X07.38MShares$84.5 Million0.09% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.7MShares$76.8 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.38MShares$73.1 Million2.43% of portfolio
-
Fcpm Iii Services B.V. Naarden, P75.46MShares$62.5 Million21.73% of portfolio
-
Rtw Investments, LP New York, NY5.22MShares$59.8 Million2.01% of portfolio
-
State Street Corp Boston, MA3.72MShares$42.6 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.86MShares$32.8 Million0.01% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA2.65MShares$30.3 Million10.2% of portfolio
Latest Institutional Activity in DYN
Top Purchases
Top Sells
About DYN
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..
Insider Transactions at DYN
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 31
2025
|
Erick Lucera Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
66,100
+50.0%
|
-
|
|
Mar 13
2025
|
Johanna Friedl Naderer Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
143
-0.15%
|
$1,716
$12.12 P/Share
|
|
Mar 11
2025
|
Oxana Beskrovnaya Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,153
-1.09%
|
$23,683
$11.38 P/Share
|
|
Mar 11
2025
|
Richard William Scalzo SVP, Head of Finance & Admin. |
SELL
Open market or private sale
|
Direct |
1,343
-1.09%
|
$14,773
$11.38 P/Share
|
|
Mar 05
2025
|
Richard William Scalzo SVP, Head of Finance & Admin. |
SELL
Open market or private sale
|
Direct |
917
-0.74%
|
$10,087
$11.83 P/Share
|
|
Mar 05
2025
|
John Cox CEO & President |
SELL
Open market or private sale
|
Direct |
4,061
-2.7%
|
$44,671
$11.83 P/Share
|
|
Mar 05
2025
|
Douglas Kerr Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,343
-1.41%
|
$14,773
$11.83 P/Share
|
|
Mar 05
2025
|
Oxana Beskrovnaya Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,094
-0.55%
|
$12,034
$11.83 P/Share
|
|
Feb 18
2025
|
Oxana Beskrovnaya Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,598
-1.29%
|
$33,774
$13.95 P/Share
|
|
Feb 18
2025
|
Richard William Scalzo SVP, Head of Finance & Admin. |
SELL
Open market or private sale
|
Direct |
2,488
-1.96%
|
$32,344
$13.95 P/Share
|
|
Jan 27
2025
|
Jason P Rhodes |
BUY
Grant, award, or other acquisition
|
Indirect |
1,111,111
+36.2%
|
$14,444,443
$13.5 P/Share
|
|
Dec 11
2024
|
Richard William Scalzo SVP, Head of Finance & Admin. |
SELL
Open market or private sale
|
Direct |
1,455
-1.13%
|
$40,740
$28.12 P/Share
|
|
Dec 11
2024
|
Oxana Beskrovnaya Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,334
-1.14%
|
$65,352
$28.12 P/Share
|
|
Dec 09
2024
|
Dirk Kersten |
SELL
Open market or private sale
|
Indirect |
34,437
-0.63%
|
$998,673
$29.18 P/Share
|
|
Dec 06
2024
|
Dirk Kersten |
SELL
Open market or private sale
|
Indirect |
101,675
-1.84%
|
$2,948,575
$29.34 P/Share
|
|
Dec 05
2024
|
Dirk Kersten |
SELL
Open market or private sale
|
Indirect |
3,806
-0.07%
|
$110,374
$29.05 P/Share
|
|
Dec 04
2024
|
Oxana Beskrovnaya Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
66,500
+14.98%
|
-
|
|
Dec 04
2024
|
John Cox CEO & President |
BUY
Grant, award, or other acquisition
|
Direct |
145,300
+49.15%
|
-
|
|
Dec 04
2024
|
Douglas Kerr Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
48,000
+33.45%
|
-
|
|
Dec 04
2024
|
Richard William Scalzo SVP, Head of Finance & Admin. |
BUY
Grant, award, or other acquisition
|
Direct |
32,700
+20.28%
|
-
|
Last 12 Months Summary
Buy / Acquisition
1.97M
Shares
From
12
Insiders
| Grant, award, or other acquisition | 1.61M shares |
|---|---|
| Exercise of conversion of derivative security | 323K shares |
| Open market or private purchase | 32K shares |
Sell / Disposition
2.8M
Shares
From
11
Insiders
| Open market or private sale | 2.8M shares |
|---|